Most patients quit Novo's Wegoby and Ozenpick within 2 years

The findings are in addition to recent research questioning long-term use of these drugs, which have a common active ingredient called semaglutide and are prescribed in the US for weight loss and diabetes, respectively.

This analysis is based on pharmacy and medical claims data provided by Prime Therapeutics, Inc., which is the pharmacy benefit manager, and represents 3,364 people with commercial health insurance covering GLP-1 drugs.

The target audience is those who have been diagnosed with obesity or a BMI of 30 or higher and who started a new prescription between January and December 2021.